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Movement is a concept we often use with many different meanings. For instance, “a 
movement” among musicians would refer to one division of a larger composition, whereas 
among physicists “movement” would be principally described as a continuous change in the 
location of a body. We also commonly refer to cultural, religious, artistic and philosophical 
“movements”.  
However, in the following thesis we will study elements involved in the generation of our 
body movements, our ability of motion. 
To achieve simple tasks we need to have our sensory system guiding our movements. In 
order to pick up an apple you must have a visual representation of where the apple is 
located in space. It also requires that you know where your hand is in space. Thus to pick 
up the apple is only possible when the brain areas in charge of the motor movement are 
constantly informed by the ongoing stream of information acquired by our sensory systems.  
Broadly speaking, voluntary movements are initiated in our cerebral cortex. They pass 
through several intermediate regulatory stations and finally reach the spinal cord where the 
movement commands are targeted to the necessary muscles.  
In this work I focus on one of these “regulatory stations”, the basal ganglia, more 
specifically on one of its nuclei: the substantia nigra. The substantia nigra is mainly known 
for its neurons that use dopamine as a neurotransmitter, and their degeneration is 
associated with Parkinson’s disease. 
My work aims to understand more about the molecular mechanism of a relevant protein 
that these neurons express, namely the dopamine transporter.  
With the following work I hope to contribute at least a little piece of information to the 
physiology of the basal ganglia by investigating the mechanism of dopamine release 










1.1. Basal ganglia 
1.1.1. The Basal ganglia functions 
The main structures and circuits involved in our everyday movement behaviour are 
(i) the motor areas in the cerebral cortex and its pyramidal track connecting the brain 
and the spinal cord, (ii) the cerebellum, which among other functions has several 
feedback circuits sensing the body position in space giving equilibrium and fine-
tuning movements, and (iii) finally the ganglia-thalamocortical system that plays an 
important role in execution, modulation and correction of voluntary movements. 
The basal ganglia have been associated with sensorimotor functions and their failure 
leads to movement disorders, such as Huntington’s disease, Hemiballism and 
Parkinson’s disease (PD). PD is characterized by hypokinesia, which consist in slow 
movements (bradykinesia), difficulty in initiating willing movements (akinesia), 
increased muscled tone (rigidity) and resting tremor. The main degenerative process 
occurring in PD is the loss of dopaminergic neurons in the substantia nigra (SN) (see 
section 1.1.3.). Huntington’s disease is a hereditary and progressive disorder 
associated not only with abnormal movements in the sense of hyperkinesias and 
chorea (involuntary uncontrollable movements), but also with psychiatric symptoms 
and eventually dementia. Huntington’s pathology is characterized by neuronal loss 
in several basal ganglia nuclei (caudate nucleus, putamen, glubus pallidus), cerebral 
cortex and other areas. Hemiballism is another hyperkinetic movement disorder with 
fast, unwilled flinging of the limbs caused by a lesion in subthalamic nucleus (STN).  
The neuronal activity leading to voluntary movement originates from motor areas in 
the cortex (motor area M1 and sensory motor area SMA). The basal ganglia act as a 





1.1.2. Basal ganglia nuclei and their connections 
The anatomical circuits within the basal ganglia consist of several interconnected 
nuclei, which receive principal afferents from the prefrontal, motor and sensory 
cortex and send various ascending and descending efferents to thalamic and 
mesensephalic structures.  
The basal ganglia consist of four nuclei; the striatum, the pallidum, the subthalamic 
nucleus (STN) and the substantia nigra (SN) (Figure 1). The striatum can be divided 
in three subregions: the caudate nucleus, the putamen and the ventral striatum, which 
includes the nucleus accumbens. The pallidum has two subdivisions, the external 
(GPe) and internal (GPi) segment. The substantia nigra can be divided also in two 
areas, the subtantia nigra pars compacta (SNc) and pars reticulata (SNr) 
 
Figure 1 | Schematic representation of some 
basal ganglia nuclei and their connections. Two 
types of dopamine receptors  (D1 and D2) are 
presented in different sets of outputs neurons in the 
striatum. The striatal neurons define what are 
known as direct and indirect pathways (referring to 
the way they reach the thalamus). Excitatory 
pathways are shown in blue, and inhibitory 
pathways in red. GPe= external segment of the 
globus pallidus; GPi= internal segment of the 
globus pallidus; STN=subthalamic nucleus; 
SNc=substansia nigra pars compacta; SNr = 






The striatum is the major recipient of inputs to the basal ganglia, coming principally 
from the prefrontal, motor and sensory cortex. The striatal inputs are strongly 
modulated by the dopaminergic neurons that reside in the SNc. This projection from 




organized. The striatum contains mainly GABAergic neurons which project to the 
basal ganglia output nuclei via the so called direct and indirect pathways (Figure 1). 
In the classical view of basal ganglia function (DeLong, 1990) these two pathways 
are affected differently by the dopaminergic projection from the SNc: Neurons of the 
direct pathway express the D1 dopamine receptors and neurons of the indirect 
pathway express D2 dopamine receptors. There are however some studies that 
contradict this classical view (Bergman et al., 1990; Wang et al., 2006)..  
The expression of motor behaviours depends very much on the basal ganglia loop, 
which is in turn strongly regulated by the SNc dopaminergic afferents. The human 
SNc contains approximately between 3 to 6x105 dopaminergic neurons (German 
and Manaye, 1993), which mainly project to the striatum. Each SNc neuron might 
have up to 150,000 presynaptic terminals in the striatum (Oorschot, 1996; Roberts 
et al., 2002). Additionally, the SNc neurons have a long apical dendrite extended 
ventrally into the subtantia nigra pars reticulata.  
The SNr and the GPi are the main output structures of the basal ganglia. They are 
GABAergic and project principally to the ventro-lateral thalamus (VLo) and the 
pedunculopontine nucleus (PPN) (Figure 1).  
 
1.1.3. Parkinson’s disease 
One of the most frequent movement disorders today in the world is Parkinson’s 
disease (PD). It is named after James Parkinson who first described some of the 
symptoms in 1817. The cardinal symptoms in PD are muscular rigidity, tremor and 
akinesia. Depending on its cause, Parkinson’s disease is principally divided into 






1.1.3.1. Epidemiology of Parkinson’s disease 
Parkinson’s disease is extensively spread. Reports indicate a prevalence of 250 cases 
per 100,000 (in the USA) and 1,700 cases per 100,000 (in China) in people older 
that 65 years (Zhang et al., 2005). An aged and gender adjusted incident rate of 
13,4 per 100,000 was established by other group in the USA (Van Den Eeden et 
al., 2003). The incidence rapidly increases over the age of 60 years, with only 4% of 
the patients being under the age of 50 years. The rate for men was 91% higher than 
for women (Van Den Eeden et al., 2003). PD cases are reported at all ages, 
however is very uncommon in people under 40. The average age at which the 
symptoms begin in the USA is 58-60 years (Fahn and Sulzer, 2004). PD is rare in 
young patients and often caused by an inherited or spontaneous genetic defect.  
 
1.1.3.2. Parkinson’s disease clinical symptoms 
Normally, PD is diagnosed when the motor parkinsonism symptoms become explicit 
and dopamine agonists are found to reduce those symptoms. The clinical 
characteristics of PD are: slowing down movement (bradykinesia), akinesias or no 
movement, rigidity and tremor.  Many spontaneous movements like arm swinging, 
blinking and swallowing are reduced or totally lost. Tremor will be maximal when the 
limb is at rest, and reduced with voluntary movement. Later during the disease there 
is a notorious failure in postural reflexes, impaired balance and general instability. 
Non-motor symptoms are also presents and some of them are: autonomic 
dysfunctions, apathy, depressions, sleep disorders, fatigue, pain and dementia.    
 
1.1.3.3. Etiology of Parkinson’s disease 
For the vast majority of PD patients, the syndrome only correlates with age and 
there is no clear explanation yet of its etiology (idiopathic PD). Only in a minority of 
patients, PD is caused by genetic and/or environmental factors (hereditary and 




Several gene loci have been implicated in autosomal dominant forms of PD 
including duplications or/and mutations in alpha-synuclein (Polymeropoulos et al., 
1997) and in LRRK2 (Zimprich et al., 2004). Other gene loci have been found to 
cause autosomal recessive form of PD, such as the gene mutations in parkin (Kitada 
et al., 1998) and in DJ-1 (Bonifati et al., 2003). Both autosomal dominant and 
recessive forms of parkinsonism usually have an early onset as compared with the 
idiopathic PD. 
There are also several environmental factors known to cause parkinsonian 
symptoms. Exposure to iron or manganese has been shown to generate reactive 
oxygen species and have been used to induce parkinsonism in laboratory animals 
(Jenner, 1998). Two important chemical examples are 1-methyl-4-phenyl-1,2,3,6-
tetra-hydropridine (MPTP) and the herbicide paraquat, which both concentrate in 
dopaminergic neurons and eventually will kill them (Langston et al., 1983; Javitch et 
al., 1985; McCormack et al., 2002). MPTP was found in poorly purified MPPP, an 
opioid analgesic drug. It is not used in clinical practice, but has been illegally 
manufactured for illicit drug use.  In the early 80´s Californian drug abusers were 
notoriously more affected with parkinsonian symptoms than the rest of the 
population, which led to the identification of MPTP. The MPTP metabolite MPP+ 
is selectively taken up by dopaminergic neurons through the dopamine transporter 
(DAT) (Langston et al., 1983; Javitch et al., 1985). MPP+ inhibits the 
mitochondrial respiratory chain, depleting the neuron from ATP. Because of its 
selective uptake this neurotoxin kills SNc neurons and causes a parkinsonian-like 
syndrome in humans and animals. It is today the best characterized animal model 
for PD. 
With the intention to explain idiopathic causes of PD, it has also been suggested 
that dopamine can be oxidized and generate a toxic derivative, dopamine quinone. 
In this reactive form, dopamine quinone can covalently bind to cysteins forming 5-
cysteinidyl-dopamine (Fornstedt et al., 1986). Cystein residues are commonly 




to a general malfunction of the neuron. In this respect high expression levels of the 
dopamine transporter (DAT) have been suggested to increase the toxic load of SNc 
neurons by increasing cytosolic dopamine (Uhl, 1998; LaVoie and Hastings, 1999). 
These processes can occur gradually and naturally, which might up to some extent 
account for the late onset of the idiopathic form of PD.  
 
1.1.3.4. Pathophysiology of Parkinson’s disease 
Post-mortem brains of PD patients showed a strong loss of dopaminergic neurons in 
the SNc. Humans need to loose between 50-70% of their SNc neurons to start 
evidencing parkinsonian symptoms (Zarow et al., 2003). The missing dopaminergic 
neurons in the SNc result in hyperactivity of STN (by less inhibition), which then 
excite excessively the inhibitory basal ganglia outputs GPi and SNr (Figure 2).   
The STN hyperactivity inhibits in a disproportionate manner the thalamus and the 
PPN. The excessive inhibition of the thalamus caused by the loss or malfunction of 
the SNc neurons, leads to a reduced excitation of the cortical motor areas (Figure 2). 
The strong inhibition of the thalamocortical system is most probably associated with 
bradykinesia and akinesia, characteristic symptoms of PD. The strong inhibition of 
the pedunculopontine nucleus (PPN) may be associated with rigidity, but this model 






Figure 2 | Schematic representation of the principal pathways affected by the loss of 
dopaminergic neurons in the Parkinson disease. Two types of dopamine receptors  (D1 and D2) 
are presented in different sets of outputs neurons in the striatum. The striatal neurons output define 
what are known as direct and indirect pathways (referring to the way they reach the thalamus). 
Excitatory pathways are shown in blue, and inhibitory pathways in red. The dashed arrows 
represent an impaired projection and the sizes of the arrows suggest the strength of the signal. The 
excessive inhibition of the thalamus caused by the loss of SNc neurons result in a poor excitation of 
the motor areas in the cortex. GPe= external segment of the globus pallidus; GPi= internal segment 
of the globus pallidus; STN= subthalamic nucleus; SNc= substansia nigra pars compacta; SNr = 
substansia nigra pars reticulata; PPN= pedunculopontine nucleus. 
 
1.2. Dendritic release of dopamine in the SN 
1.2.1. Anatomy of substantia nigra pars reticulata  
The substantia nigra pars compacta consists of packed large dopaminergic neurons 
projecting to the striatum. Neurons in the adjacent pars reticulata (SNr) are 
GABAergic and project mainly to the thalamus and the pedunculopontine nucleus 
(PPN) (Figure 1). The long apical dopaminergic dendrites of SNc extend mainly into 
the SNr. Many different afferents converge in the SNr, since it is an output nucleus 
of the basal ganglia. The principal afferent fibers projected to the SNr originate from 
the striatum, the pallidum and from the STN. The STN is the only excitatory 




Interestingly, dopamine is not only found at the SNc axon terminals in the striatum, 
but also in the SNr dopaminergic dendrites (Björklund and Lindvall, 1975). Even 
more, it has been shown that SN neurons can release dopamine from their dendrites 
in the SNr (Geffen et al., 1976). Accordingly, dendritic release of dopamine in the 
SNr has been observed by several groups (Geffen et al., 1976; Cheramy et al., 
1981; Mintz et al., 1986; Rosales et al., 1994; Falkenburger et al., 2001).  
Dopamine release in the SNr has been shown to be modulated by GABAergic 
afferents from the internal segment of the globus pallidus (Cobb and Abercrombie, 
2003) and enhanced by stimulation of the glutamatergic subthalamic nucleus 
afferents (Mintz et al., 1986; Rosales et al., 1994; Falkenburger et al., 2001). 
 
1.2.2. Function of dopamine release in the SNr 
It is one of the most striking findings that dopamine can alter the activity of SNr 
neurons, although there are no formal dopaminergic synapses in this area. 
Dopamine can modulate SNr neurons through presynaptic receptors on striatal, 
pallidal and subthalamic afferents (Ruffieux and Schultz, 1980; Martin and 
Waszczak, 1994; Trevitt et al., 2002; Ibañez-Sandoval et al., 2006; Windels and 
Kiyatkin, 2006). Moreover, dopaminergic neurons in the SN express dopamine 
inhibitory D2 autoreceptors.  
Since the SNr constitutes one of the major output pathways from the basal ganglia, 
nigral dopamine and dopamine receptors have been shown to affect a variety of 
behaviours (Robertson and Robertson, 1989; Trevitt et al., 2001; Andersson et al., 
2006).  
 
1.2.3. Mechanism of dendritic dopamine release in the SNr 
Findings on the mechanism of dopamine release in the SN and on its calcium-




neurons located in the SNc have been reported to be quantal, sensitive to Cd+2 (Jaffe 
et al., 1998) and dependent on extracellular calcium (Rice et al., 1997). Similarly, 
somatodendritic release from cultured primary midbrain dopaminergic neurons was 
reduced (but present) in the absence of extracellular calcium and was sensitive to 
botoulinum toxin A and B (Fortin et al., 2006).  
On the other hand, dendritic dopamine release in the SNr has been reported to be 
insensitive to Cd+2 (Hoffman and Gerhardt, 1999), insensitive to blockers of VGCC 
(Chen et al., 2006), present in the absence of extracellular calcium (Chen and Rice, 
2001; Falkenburger et al., 2001) and sensitive to the dopamine transporter blocker 
GBR12935 (Falkenburger et al., 2001).  
Taken together, these findings support the existence of exocytotic release from the 
somata of dopaminergic neurons in the SNc and of DAT-mediated release from the 
long apical dendrites of dopaminergic neurons in the SNr. These two types of non-
axonal release are consistent with the localization of the DAT, which can be found 
on dendritic but not on perikaryal plasma membranes (Nirenberg et al., 1996). Our 
further interest will focus in the properties of the DAT to mediate dopamine release 
in the SNr. 
 
1.3. The dopamine transporter (DAT) 
1.3.1. Catecholamine transporters 
The family of catecholamine transporters share a high identity in their amino acid 
sequence (Figure 3). The DAT belongs to the SCL6 family of Na+ symporters, 
which also includes transporters for the biogenic amines serotonin and 
norepinephrine (SERT and NET respectively) as well as for the inhibitory 
transmitters GABA and glycin (Masson et al., 1999).  
The dopamine transporter is an electrogenic, secondary active co-transporter of 




Corey et al., 1994; Gu et al., 1994). Sequence analysis suggested the presence of 
12 trans-membrane domains for the DAT and its homologs (Edvardsen and Dahl, 
1994). And indeed, the first high resolution x-ray structure of a prokaryotic leucine 
transporter (LeuTAa) homolog to the mammalian SCL6 family of transporters shows 
12 trans-membrane domains (Yamashita et al., 2005). This has provoked 
considerable interests in the understanding of substrate binding, channel-like 
behaviour, non-competitive inhibition, topology and functional molecular mechanism 
of the mammalian neurotransmitter transporters. 
 
 
Figure 3 | Amino acid sequence and topology of monoamine transporter proteins. A: 
Amino acid alignment of the human dopamine transporter, noradrenaline transporter and 5-HT 
transporter. Identical residues are shown in red, whereas similar residues (V, L, and I, K and R, F 
and Y, or D and E) are shown in orange. Asparagine residues that form part of N-linked 
glycosylation consensus sequences are shown in blue. A conserved aspartate residue in 
transmembrane domain 1 that is presumably involved in the interaction with monoamines is shown 
as a yellow box. A leucine-repeat in transmembrane domain 2, and a glycophorin-like motif in 
transmembrane domain 6 are shown in green. The intracellular loop between transmembrane 
domain 6 and 7 contains several residues involved in conformational changes during substrate 
binding and translocation is shown in blue. Black bars represent putative transmembrane domains. 
The colour boxes covering the parts of the intracellular carboxyl termini represent interacting sites 
with Hic-5 (beige), synuclein (grey), and PICK1 (purple). DAT, dopamine transporter; h, human; 
NET, noradrenaline transporter; SERT, 5-hydroxytryptamine transporter. B: Proposed topology of 




1.3.2. DAT localization 
The DAT can be considered a specific marker of dopaminergic neurons since it is 
exclusively expressed on them (Giros and Caron, 1993; Ciliax et al., 1995). In situ 
hybridization of human brains showed a prominent DAT expression principally in 
substantia nigra (SN) and ventral tegmental area (VTA) neurons (Hoffman et al., 
1998). In mouse it can be also found in relatively big quantities in the nucleus 
accumbens, olfactory tubercle and nigrostriatal bundle (Freed et al., 1995). At cellular 
level, it has been described to be enriched on dendrites and axon terminals. 
(Nirenberg et al., 1996). 
 
1.3.3. The dopamine transporter’s functional properties 
In general, the catecholamine transporters´ classical function is the uptake of 
monoamines that have been released into the synaptic cleft, thus regulating the 
neurotransmitters concentration and time of action (Figure 4). One of the firsts hints 
of the uptake mechanism in catecholamine transporters was envisioned by the work 
of Krueger in 1990. Today we know that the DAT co-transports two ion of Na+ and 
one of Cl- together with one molecule of dopamine (Krueger, 1990; Gu et al., 1994). 
The Cl- presence seems not to be critical for its dopamine uptake function. On the 
contrary the sodium gradient is the main necessary driving force. For this reason the 
existence of a well-defined Na+ gradient is very important. It is normally sustained 






Figure 4 | Schematic representations of dopamine, noradrenaline and 5-HT synaptic 
terminals. Monoamine transporters are localized in perisynaptic sites, where they are crucial for 
the termination of monoamine transmission and the maintenance of presynaptic monoamine 
storage. Several selective pharmacological agents acting at each monoamine transporter are shown. 
Amph., amphetamine; DA, dopamine; DAT, Dopamine transporter; L-DOPA, L-3,4-
dihydroxyphenylalanine; 5-HT, 5-hydroxytryptamine; MPP+, 1-methyl-4-phenylpyridinium; 
MDMA, (+)-3,4 methylenedioxymethamphetamine; NA, noradrenaline; NET, noradrenaline 
transporter; SERT, 5-HT transporter. Figure and legend taken entirely from Torres et al. 2003 
(Torres et al., 2003).. 
 
In addition to the DAT’s classical function, the DAT has been shown to release 
dopamine. However, the DAT´s property of releasing dopamine has not been 
investigated as thoroughly and mainly as an effect of amphetamine and its 
derivatives (Heikkila et al., 1975; Melega et al., 1995; Sonders and Amara, 1996), 
which are among the most widely abused psychostimulants. The mechanism of 
amphetamine-induced dopamine efflux, has been attributed to a variety of different 
factors, making this a field of study by it self (Sulzer et al., 2005). In the next section 
we will review some of the mechanism proposed for amphetamine-stimulated 
dopamine release.  
 
1.3.4. Amphetamine-induced dopamine release 
It took several years to differentiate compounds that block the dopamine uptake 
from the ones that induced a DAT-mediated dopamine release. Cocaine was 
related to blocking catecholamine transporters in 1960 (Whitby et al., 1960), but it 
was only in 1997 when Sonders et al. could convincingly differentiate between 




associated ion currents. Since then, amphetamine is believed to be a dopamine 
transporter substrate and to induce dopamine efflux. However amphetamine’s 
mechanism of action is still not entirely understood. There are at least four 
hypotheses and one emerging new possibility of how amphetamine may induces the 
reverse transport.   
 
1.3.4.1. Facilitated exchange diffusion theory 
In 1973 Paton (inspired by a work done in glucose transport) described a possible 
mechanism known as “facilitated exchange diffusion” (Paton, 1973). When 
amphetamine is transported into the cell through the DAT, then dopamine, which is 
in higher concentration intracellularly, interacts with the cytosolic binding site of the 
DAT. When the DAT moves back to its “natural” position (with the binding site 
facing the extracellular space) it transports the dopamine outside the cell. This would 
mean that for each molecule of amphetamine that is taken up one molecule of 
dopamine is released. However, this latter consequence for this model has been 
difficult to conciliate with many recent studies.  
 
1.3.4.2. The weak base hypothesis 
This hypothesis takes into account the chemical properties of amphetamine. 
Amphetamine is a week base and can freely diffuse through membranes. The 
vesicular monoamine transporter (VMAT) uses the vesicle pH gradient to 
concentrate catecholamines in the vesicle lumen. An alkalinization of the vesicles by 
the amphetamine base properties was proposed. This would disrupt the pH 
gradient and induce the monoamines to move into the cytosol increasing their 
concentration by several folds (Sulzer and Rayport, 1990). Unfortunately there are 
some effects that cannot be explained by this model. For example, 3 µM 
amphetamine induced release of 70% of the previously accumulated dopamine, but 




that amphetamine has an effect in vesicular dopamine, but cannot explain the strong 
release observed.  
 
1.3.4.3. Increase of intracellular sodium  
This hypothesis was proposed in 2003 when it was shown using sodium sensitive 
dyes that the uptake of amphetamine by the DAT leads to a change in cytosolic 
sodium concentrations. Accordingly the authors showed that amphetamine-induced 
dopamine efflux was voltage-dependent, electrogenic, and dependent on 
intracellular Na+ concentration in the recording electrode (Khoshbouei et al., 2003). 
The DAT dopamine uptake is primarily sodium dependent (Krueger, 1990; 
McElvain and Schenk, 1992; Gu et al., 1994). The maintenance of the sodium 
gradient, keeps the cytosolic dopamine concentration high. Therefore a loss or 
reduction of the cellular sodium gradient will result in dopamine efflux. Consistently, 
dopamine release has been induced by opening sodium channels with veratridine 
(Elverfors et al., 1997). 
 
1.3.4.4. Transient channel-like mode of the DAT  
The next hypothesis is known as the “channel-like mode”. Transport-associated ion 
currents were shown before, but in 1998 Galli and co-workers demonstrated a 
channel-like opening of the norepinephrine transporter (NET) by combining patch 
clamp with amperometric recordings (Galli et al., 1998). Recently, using outside-out 
patches Kahlig et al. (2005) showed that the DAT could perform milliseconds burst 
of dopamine release in a channel-like behaviour during amphetamine stimulation 







1.3.4.5. Role of DAT phosphorylation 
A new hypothesis is emerging from recent evidences. They suggest that DAT 
phosphorylation might play a role in reversal of the transport direction. The mutation 
of 5 serines at the DAT N-terminal abolished amphetamine-induced dopamine 
efflux (Khoshbouei et al., 2004). It was also suggested that the phosphorylation 
would shift the DAT from a “reluctant” to a “willing” state that would favour 
amphetamine-induced dopamine release (Khoshbouei et al., 2004). Furthermore 
amphetamine-induced dopamine release was inhibited by downregulation or 
inhibition of protein kinase C (PKC) (Kantor and Gnegy, 1998) and by inhibition of 
CaMKII (Fog et al., 2006).  
Since the Na+ and Cl- electrochemical gradients energy drive the DAT monoamine 
translocation, it would be very interesting to understand how DAT phosphorylation 
would make dopamine release energetically favourable.    
 
1.3.5. Glutamate-induced DAT reversal  
Even though the exact mechanism is not entirely resolved, it is important to note 
that amphetamine revealed the capacity of the DAT to transport in reverse mode, 
mediating an efflux of dopamine. The field of amphetamine-induced dopamine 
release now meets with evidences that the DAT can physiologically (without 
amphetamine) induce DAT-mediated dopamine release. It has been shown that 
the activation of glutamatergic subthalamic afferent induces a dopamine release into 
the SNr, which is sensitive to the DAT blocker GBR12935 and independent of 
extracellular calcium. In addition Falkenburger et al. (2001) have demonstrated that 
ionotropic glutamate receptors are not necessary for DAT-mediated dopamine 
efflux, suggesting that the physiological activation of metabotropic glutamate 
receptor could be sufficient to induce the reversal of the DAT (Falkenburger et al., 
2001). The main metabotropic glutamate receptors (mGluRs) found in SNr were 




release intracellular calcium and activates PKC through Gq or Gq/11 protein. This is 
interesting, since amphetamine has been recently showed to need PKC activation 
and DAT phosphorylation to induce DAT-mediated dopamine efflux.  
 
1.3.6. Role of the DAT in Parkinson’s disease 
As we described previously (section 1.1.3.3.), the DAT takes up several neurotoxins 
selectively into dopaminergic neurons, this might be the responsible for some 
environmental or symptomatic PD. Some examples of identified compounds are 
MPTP (widely used for PD animal model)(Langston et al., 1983), paraquat 
(herbicide)(McCormack et al., 2002), rotenone (insecticide) (Gao et al., 2002), 
maneb (fungiside) (Thiruchelvam et al., 2000) and other compounds. 
Additionally, today the DAT provides an important tool to observe dopaminergic 
terminal in living subjects, by using single photon emission computed tomography  
(SPECT) or positron emission tomography (PET). This property has improved the 
diagnosis of PD.  
Even though the DAT is one of the most important elements in the regulation of 
extracellular dopamine en the striatum, its relevance in Parkinson’s has not been 
entirely elucidated. Moreover, the new findings of DAT-mediated dopamine 
release in the SNr imply that the DAT properties might affect animal behaivior by 
mediating dopamine efflux in the basal ganglia output SNr (Bergquist et al., 2003; 
Andersson et al., 2006).  
 
1.3.7. Role of the DAT in drugs of abuse 
Several natural and synthetic compounds are known to block or act as substrate of 
the catecholamine transporters (Figure 4). Some of them like fluoxetine (Prozac) are 
used to treat depressions and methylphenidate (Ritalin) is used to treat attention-





The relation of the DAT with several drugs of abuse has been in fact the main 
interest of its investigation. Cocaine blocks the DAT and increases the concentration 
of dopamine in the synapses over time whereas amphetamine in addition induces 
dopamine release through the DAT (Figure 4). Although both of them act relatively 
unselective among the cathecolamine transporters, it seems to that their behavioural 
and reinforcement effect depend mainly on their interaction with the DAT (Wise, 
1996). Another illegal drug is 3,4-methylenedioxy-N-methylamphetamine or 
MDMA (Ecstasy). It is an amphetamine derivative and similarly it also induces 
reverse transport, but in this case with a higher affinity to the SERT (Rudnick and 










1.4. Aims of this study 
The aim of this study was to investigate the signalling which mediates the 
glutamate-induced reversal of dopamine transport in the SNr.  
In the light of previous observations, we are exploring the possibility that glutamate-
induced dopamine efflux in the SNr could be mediated by the metabotropic 
glutamate receptors (mGluRs). Since both glutamate and amphetamine are able to 
induce reversal of dopamine transport (Sonders et al., 1997; Falkenburger et al., 
2001), we tested to which degree the mechanisms used by glutamate and 
amphetamine were similar or different from one another.  
We are exploring the possibility that the activation of a second messenger signalling 
cascade induces DAT-mediated dopamine release (Figure 5). This possibility is 
intriguing, since it might not only explain the mechanism of glutamate-induced 
dopamine release in the SNr but also could demonstrate that amphetamine uses a 
physiological signalling cascade to have its effect. 
To achieve this end, we used amperometric recordings in brain slices, measurements 
of dopamine efflux from cell lines engineered to express WT and mutated DAT, a 
new imaging approach to visualize dopamine uptake and release, and in a 
collaboration with Lucian Medrihan, patch-clamp recordings of dopaminergic 
neurons. 
Figure 5 | The cartoon 
represents some elements in 
the SNr synapsis. It was 
shown that inhibition of 
AMPA and NMDA glutamate 
receptors did not abolish 
DAT-mediated dopamine 
release in the SNr. Whether 
the mGluR group I is the 
responsible for reversal of the 
DAT remains unclarified. 
Dopamine release could 
activate D2 dopamine 
receptors in SNr, modulating 
several neighbours’ neurons.  
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2. Materials & Methods 
 
 
2.1. Materials  
All Chemicals were obtained from Sigma-Aldrich unless otherwise stated. 
 
2.2. Brain slices:  
Acute parasaggital rat brain slices were prepared as described previously 
(Falkenburger et al., 2001). Wistar rats, 10-16 days old, were decapitated and 
350µm thick parasaggital slices of substantia nigra cut on a VT1000 vibratome 
(Leica) in ice cold artificial cerebro-spinal fluid (ACSF) containing: NaCl 125 mM, 
KCl 2.5 mM, CaCl2 2 mM, MgCl2 1 mM, NaHCO2 26 mM, Na3PO4 1.25 mM, 
glucose 25 mM, equilibrated with 95% O2 and 5% CO2 resulting in pH = 7.4.  
 
2.3. Amperometry  
Amperometry was performed as previously described (Falkenburger et al., 2001). 
Currents were recorded at 800 mV using a carbon fiber (SF1A, 30 µm diameter, 
Center for Sensor Technology) and an Axopatch 200B amplifier (Axon 
Instruments). The carbon fiber was inserted 200-300 µm into a substantia nigra 
slice constantly superfused with calcium-free ACSF, for which 2 mM CaCl2 was 
replaced by 2 mM MgCl2 and 1 mM EGTA (RT, 1 ml/h). Glutamate (1 mM in 
0.9% NaCl), PMA (10 µM in 0.9% NaCl; stock was 100 mM in DMSO; Tocris, 
Bristol; UK), trans-ACPD (1 µM in 0.9% NaCl; Tocris) were applied at a constant 
distance to the carbon fiber using a patch pipette and a pressure pulse (20 psi, 10 s, 
Picospritzer). Currents were digitized using a Digidata interface, recorded by 
pCLAMP 9 (Axon Instruments). IGOR-Pro (WaveMetrics, Oregon, USA) was 
used for data visualization. Glutamate, PMA and trans-ACPD were applied every 
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30 minutes. Antagonists were bath-applied: GBR12935 (20 µM in ACSF) and 
chelerythrine (10 µM in ACSF).  
 
2.4. Molecular biology and Cell culture 
To generate cell lines that stably express DAT, the cDNA of the human dopamine 
transporter (hDAT1, obtained from Ulrik Gether, Department of Pharmacology, 
University of Copenhagen; Denmark) was subcloned into the pcDNA3.1(+) vector 
(Invitrogen, Karlsruhe, Germany) using HindIII and XbaI restriction enzymes 
(Fermentas, St. Leon-Rot, Germany) and the sequence verified. The N-terminal 
truncation was achieved by using the site directed mutagenesis kit (Stratagene). The 
primers Fw: CCGTGGAAGCTTCGGC TATGGAGCCCAATGCCG and 
Rv: CGGCATTGGGCTCCATAGCCG AAGCTTCCACGG, generated a 
new HindIII restriction site at position 16 (A16) and a starting metionine codon 
replaced the K19M. Mutated DNA was then digested overnight with HindIII and 
gel purified (QIAquick Gel Extraction kit, Quiagen). Digested DNA followed an 
overnight re-ligation with T4 DNA ligase (fermentas). Finally sequence was 
verified.  
SH-SY5Y cells were transfected using nucleofection (amaxa AG, Cologne, 
Germany), following the manufacturer’s instructions. Cells were cultured in 
Dulbecco’s MEM (PAN-Biotech, Aidenbach, Germany) with 15% fetal calf serum 
and 1% penicillin-streptomycin. 24 h after nucleofection, the medium was 
supplemented with 1 mg/ml of G418 (Biochrom AG, Berlin, Germany). Medium 
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2.5. Measuring dopamine uptake and release by HPLC  
100x103 DAT-expressing SH-SY5Y cells per well were seeded 12 well plates 
(Corning). After 24 h the medium was exchanged with a modified ringer buffer 
(RB), containing 25 mM HEPES; 120 mM NaCl; 5 mM KCl; 2.5 mM CaCl2; 1.2 
mM MgSO4; 2 mg/ml glucose; 0.2 mg/ml ascorbic acid and 1 µM pargyline (pH 
7.4). For dopamine uptake, RB was supplemented with 15 µM DA. After 1h 
incubation at 37°C cells were placed on ice. The RB was removed and cells were 
washed twice with ice-cold dopamine-free RB. Then 200 µl of room temperature 
RB containing the drugs or vehicle (control) were added per each well. After 5 min 
at 37°C, 180 µl per well of (extracellular) ringer buffer were transferred to vials 
containing 20 µl of 1 M perchloric acid. The remaining buffer in the well was 
aspirated and cells were washed once with ice-cold RB free of dopamine. Cells were 
lysed by addition of 200 µl of 3% trichloroacetic acid. After 10 minutes at room 
temperature 180 µl per well of cell lysate were transfered to vials containing 20 µl of 
1 M perchloric acid. All vials were centrifuged (5 minutes, 1000 g, 4°C) and 20 µl of 
supernatant loaded onto a reverse-phase column (prontosil 120-3-C18, Bischoff, 
Leonberg, Germany). Dopamine was detected electrochemically using an ESA 
Coulochem II detector with a 5011A analytical cell (400 mV) as described 
previously (Kowsky et al., 2007). Each litter of the mobile phase contained 105 ml 
methanol (MERK) 6.973 g of sodium acetate; 0.048 g of EDTA; 7.355 g of citric 
acid mono hydrated; 0.105 g octane sulfonate. pH 4.3 was reached using 
concentrated citric acid. For each run, standards of 0.15 µM, 0.3 µM and 1.5 µM of 
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2.6. ASP+ imaging 
Custom-build imaging dishes were used for imaging, consisting of 3 cm diameter 
petridishes with a central 20 mm hole, to which a 25 mm coverslip was attached 
using Sylgard 184 (World precision Instrument Inc.). Chambers were sterilized by 
UV light. 150x103 DAT-expressing SH-SY5Y cells per dish were seeded and used 
24 h later. Cells were washed with room temperature RB and superfused with RB 
alone, RB with 10 µM ASP+ and 30 µM trypan blue or RB with 10 µM ASP+, 30 
µM trypan blue and 50 µM carbachol or 50 µM amphetamine. Basic protocol while 
acquiring images was: the firs 30s was only RB, 2 minutes of 10 µM ASP+ 30 µM 
trypan and then 5 minutes of RB. Followed by 1 minute of 10 µM ASP+ 30 µM 
trypan and 1 minute of 10 µM ASP+ 30 µM trypan + the Drug (Carbachol or 
Amphetamine) and then 5 minutes of RB. Then 2 minutes of 10 µM ASP+ 30 µM 
trypan and then 5 minutes of RB. Images of 512x512 pixels were acquired every 3 s 
using a Zeiss LSM510 confocal microscope. Excitation was done with a 488 nm 
argon laser and emission was detected after the LP560 nm long pass filter. Image 
analysis was done using ImageJ 10.2 software and IGOR-Pro.  
 
2.7. Calcium imaging  
Cells were cultured in the same custom-build imaging dishes as explained above. 
They were washed once and incubated for 30 minutes in RB supplemented with 50 
µM Fluo-4 AM (Molecular Probes, Leiden, The Netherlands). Fluo4 AM stock 
solution was dissolved in DMSO and Pluronic acid F-127 (Molecular Probes). The 
final concentrations of DMSO and Pluronic F-127 did not exceed 0.5% and 0.1%, 
respectively. After the 30 minutes incubation cells were washed twice with RB and 
mounted for imaging them. Calcium was monitored using a Leica DM6000 
epifluorescence microscope. One Image every 3 seconds was acquired using the AF 
Leica software. Image analysis was done using ImageJ and IGOR-Pro software.  
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2.8. Electrophysiological Recordings  
Whole cell patch clamp recordings were performed in pars compacta dopaminergic 
neurons from acute slices from 12-16 days old Wistar rats. The bath solution in all 
experiments consisted of ACSF. The pipette solution for all experiments contained: 
140 mM KCl, 1 mM CaCl2, 10 mM EGTA, 2 mM MgCl2, 4 mM Na3ATP, 0.5 
mM Na3GTP, 10 mM HEPES pH 7.3. Spontaneous excitatory PSCs (sEPSCs) 
were recorded in the presence of 1 µM bicuculine. After stable recordings of 3 
minutes, GBR12935 (20 µM) and sulpiride (10 µM) were subsequently added in 
the bath. Signals with amplitudes of at least 2 times above the background noise 
were selected. Patches with a serial resistance of >20 MΩ, a membrane resistance of 
<0.2 GΩ, or leak currents of >300 pA were excluded. The membrane currents were 
filtered by a four-pole Bessel filter at a corner frequency of 2 kHz, and digitized at a 
sampling rate of 5 kHz using the DigiData 1322A interface (Molecular Devices, 
Sunnyvale, CA). Statistical analysis was performed with a two-tailed paired t test. 
Data acquisition and analysis was done using commercially available software: 
pClamp 9.2 (Molecular Devices, Sunnyvale, CA), MiniAnalysis (SynaptoSoft, 










 3.1. Glutamate-induced release of dopamine requires DAT and PKC 
We used amperometry to directly measure extracellular levels of dopamine in rat 
brain slices, specifically in the SNr. To exclude the possibility of dopamine being 
released by exocytotic events, we kept the slice under continuous flow of artificial 
cerebro-spinal fluid (ACSF) containing no calcium, 1 mM EGTA and 3 mM 
magnesium. Local puff application of glutamate evoked a reproducible increase of 
oxidative current detected by the carbon fiber held at 800 mV. This current 
represents the oxidation of the released dopamine (Figure 6). Glutamate puff 
application was repeated every 30 minutes, without moving the puff pipette or the 
carbon fiber. Application of 20 µM of the DAT antagonist GBR12935 in the 
superfusing ACSF resulted in a significant reduction of the glutamate-induced 
dopamine release (block: 83.2 ±14.8%, n=5).  
 
 
Figure 6 | Glutamate induced dopamine release in brain slices. Representative traces of 
dopamine oxidative currents are shown. Puff locally applied with 1mM of glutamate, triggered a 
strong dopamine release (control). After 1h of superfusing with 20 µM of the DAT antagonist 
GBR12935, glutamate induced dopamine release is significantly blocked. After 1 h of washing in 
control ACFS, glutamate induced dopamine releases showed complete recovery as in the initial 
control condition (wash). Carbon fiber and the puff application pipettes were positioned in the SNr 
and kept there throughout the whole experiment. Carbon fiber was held constantly at 800 mV for 
dopamine oxidation. Glutamate puff duration was of 10 seconds at 20 psi. All buffers and solutions 





If dopamine would go out of the cell by other mechanisms than by reversal of the 
DAT, extracellular dopamine levels would have been increased by blocking its 
uptake with GBR12935. Since we observed a decrease of dopamine release with 
GBR12935, we concluded that dopamine had been released through the DAT. To 
rule out that the decrease in amplitude after bathing with GBR12935 had resulted 
from a rundown of the signal, we washed out the inhibitor and dopamine release 
was fully recovered (Figure 6). 
Falkenburger et al. (2001) had shown that glutamate induced dopamine efflux in 
the SNr was insensitive to the inhibition of ionotropic glutamate receptors (NMDA 
and AMPA). Their results suggested but did not prove that metabotropic glutamate 
receptors (mGluRs) are playing an important role in the reversal of the DAT. In 
addition, Kosinski in 1998 and Testa in 1994 have shown that mGluR1, a member 
of the group I mGluRs, is the most abundantly expressed mGluR in dopaminergic 
neurons. Taking this into account, we decided to apply the selective group I mGluR 
agonist trans-ACPD locally. The dopamine release triggered by the application of 
trans-ACPD was not only reproducible but was also reversibly blocked by 
GBR12935 (block: 70.7 ±14.5%, n=3) (Figure 7).  
 
 
Figure 7 |  Trans-ACPD induced dopamine release in brain slices. Representative current 
traces of recorded dopamine oxidative currents. A: Puff locally applied with 1 mM of trans-ACPD, 
triggered dopamine release (control). After 1 h of superfusing with 20 µM GBR12935, trans-ACPD 
induced dopamine release is blocked. Finally after 1 h of washing, trans-ACPD induced dopamine 
release shows recovery as in control condition (wash). Carbon fiber and the puff application 
pipettes were positioned in the SNr and kept there throughout the whole experiment. Carbon fiber 
was hold constantly at 800 mV for dopamine oxidation. Puff duration was of 10 seconds at 20 psi. 






Activation of the group I metabotropic glutamate receptors appears to be sufficient 
to induce dopamine efflux through the DAT in the SNr of rat brain slices. Although 
trans-ACPD induced a significant and reproducible dopamine release, the 
amplitude of the signal was not comparable to the one induced by glutamate, which 
means that trans-ACPD is less potent or less effective than glutamate in inducing 
dopamine release. Trans-ACPD has been reported to be 10 folds less potent than 
glutamate in activating metabotropic receptors (Sayer et al., 1992; Pin and Bockaert, 
1995). 
The mGluRs are pharmacologically classified into groups (I, II and III). Group I 
consists of mGluR1 and mGluR5, both are associated with the Gq signalling 
cascade, which activates phospholipase C (PLC), cleaves phosphatidylinositol 
bisphosphate (PIP2) producing dyacylglycerol (DAG) and inositol triphosphate 
(IP3). IP3 then induces the release of calcium from internal stores; Ca+2 binds to the 
C2 domain of the conventional and novel PKC isoforms and induces its migration to 
the plasma membrane. Once recruited there, it interacts with DAG, which makes 
PKC ready to phosphorylate its substrate (Newton, 2003) 
Since dopamine release can be triggered by the activation of a metabotropic 
glutamate receptor, it makes sense to explore the role of PKC for the reversal of the 
DAT. Therefore we first applied locally in the SN slice the phorbol ester PMA, a 
PKC activator. The strong release induced by PMA (Figure 8A) was comparable to 
the dopamine released by glutamate and, similarly, it was reversibly inhibited by 
GBR12935 (block: 93.7 ±7.5%, n=6). This showed that PKC activator PMA was 
sufficient to trigger a strong DAT-mediated dopamine release. 
To further test the responsibility of PKC in the reversal of the DAT, we examined 
whether PKC was necessary for the glutamate-induced dopamine release. And we 
found that the glutamate-induced release was reversibly inhibited by the selective 





Figure 8 | PKC activator induces dopamine release and chelerythrine inhibits glutamate-
induced dopamine release. Representative current traces of recorded dopamine oxidative currents. 
A: Puff locally applied with 10 µM of the PKC activator PMA, triggered dopamine release 
(control). After 1 h of superfusing with 20 µM GBR12935, PMA induced dopamine release is 
blocked. Finally after 1 h of washing PMA induced dopamine releases showed recovery as in 
control condition (wash). B: Puff locally applied with 1 mM of glutamate, triggered a strong 
dopamine release (control). After 1h of superfusing with 10 µM selective PKC inhibitor 
chelerythrine, glutamate induced dopamine release is significantly blocked. After 1 h of washing, 
glutamate induced dopamine releases showed almost complete recovery as in the previous control 
condition (wash). Carbon fiber and the puff application pipettes were positioned in the SNr and 
kept there throughout the whole experiment. Carbon fiber was held constantly at 800 mV for 
dopamine oxidation. Puff duration was of 10 seconds at 20 psi. All buffers and solutions were 
calcium free. The dashed horizontal line represents the baseline current. 
 
The results presented in this section indicate that PKC is a crucial player in the 
reversal of the DAT. These findings are consistent with several studies that showed 
that PKC activation is necessary for amphetamine-induced dopamine release 
(Kantor and Gnegy, 1998; Cowell et al., 2000; Johnson et al., 2005; Seidel et al., 
2005). Calcium-calmodulin kinase II (CaMKII) has also been recently implicated in 
the amphetamine-induced dopamine release (Kantor et al., 1999; Fog et al., 2006). 
In our hands, however, glutamate induced dopamine release in the SNr was not 





In summary, earlier evidence that dendritic dopamine can be released upon a 
glutamatergic stimulus in the SNr are confirmed here. In addition, our data provide 
new insights into the mechanism of DAT reversal. We showed that the group I 
mGluR agonist trans-ACPD induces dopamine release mediated by the DAT. 
Even more, activation of PKC by PMA was sufficient to trigger dopamine release. 
Glutamate-induced dopamine efflux was blocked by the selective PKC inhibitor 





















3.2. Gq-PLC signalling induces DAT-mediated dopamine release in a cell 
line 
To reduce the number of variables that have an influence on the release of 
dopamine, we then turned to a neuronal cell line; SH-SY5Y cells were transfected 
with a pcDNA3.1(+) plasmid containing the human dopamine transporter and a 
neomycin resistance gene. Selection was made using the antibiotic G418 to finally 
obtain stable expression of the DAT (these cells will be called SH-DAT).  
To measure uptake of dopamine by the cells, they were incubated with 15 µM 
dopamine in ringer buffer. The results were fit to a one-phase exponential curve 
(Figure 9). The 95% confidence interval of the half-life for dopamine uptake was 4.5 
– 12 minutes. 
Figure 9 | Extracellular dopamine is 
taken up by SH-DAT cells. Black symbols 
represent average and error bars the 
standard deviation of a triplicate 
measurement (three wells, same 
experiment). The trace in red is the fit to an 
exponential decay curve. The uptake half-
life was 6.6 minutes. The dash-line 
represents the 95% confidence interval of 




To investigate release of dopamine, cells were loaded with 15 µM dopamine for 60 
minutes. Cells were then washed twice with cold dopamine-free ringer solution, 
followed by the addition of the agent under study or the vehicle control. In each 
experiment, three wells were analyzed per condition. Extracellular medium was 
removed to measure the dopamine concentration in it. Then cells were washed again 
with cold dopamine-free ringer solution and finally lysed to measure the dopamine 
remaining inside. Note that the absolute concentration of dopamine varied between 




data from different experiments for Tables 1, 2 and 3, values were therefore 
normalized with respect to the control condition.  
Amphetamine is known to produce dopamine efflux through the DAT (Sulzer et al., 
1995). In order to test our system, we therefore exposed dopamine-loaded SH-
DAT cells to 50 µM of amphetamine. Dopamine was measured in the extracellular 
buffer and in the cells after lysis (Figure 10A). Amphetamine induced a very strong 
dopamine release, reflected by the increase of extracellular and the reduction of 
intracellular dopamine, when compared with control. Additionally, we co-incubated 
amphetamine with the DAT inhibitor GBR12335, which inhibited dopamine 
release induced by amphetamine (Figure 10B).  
 
 
Figure 10 |  Amphetamine stimulated dopamine efflux from SH-DAT cells. Cells were 
preloaded for 1h in RB with 15 µM dopamine at 37°C. After washing, cells were treated with the 
respective agent. A: dopamine concentration in the extracellular (medium) and intracellular volume 
(cells) with and without amphetamine (AMPH) B: Extracellular dopamine after the application for 
5 minutes of AMPH alone or with the DAT inhibitor GBR12935. Amphetamine (AMPH) was used 
at 50 µM; GBR12935 20 µM and Control is only the ringer buffer. Representative figures done in 
triplicate wells. The error bars represent the standard deviation of the three wells. One-way 
ANOVA with Tukey's Multiple Comparison Test was done. All differences were very significant 
***p<0.001. Multiple experiments were summarized in table 1 and 2. 
 
Although the effect of GBR12935 was not a complete block (49.9% ±11.9%; n=3), 
it reduced extracellular dopamine and showed that the amphetamine-induced 
dopamine release was through the DAT. Normal SH-SY5Y cells did not uptake 
dopamine during the loading step and accordingly did not react to amphetamine 




In summary, this outcome demonstrates that the SH-DAT system is capable to take 
up dopamine. Moreover it reacts as expected to an amphetamine stimulus. With 
this neuronal cell line expressing a functional DAT, we therefore wanted to take 
further the results obtained with the amperometric recordings in SNr. Unfortunately, 
we were not able to detect mGluR in our SH-DAT cells by immunobloting with 
specific monoclonal antibodies against mGluR1 or mGluR5 (data not shown), and 
the SH-DAT cells did not change cytosolic calcium in response to glutamate or the 
mGluR agonist Trans-ACPD (see imaging section below, Figure 23). This indicates 
that our SH cell lines do not express mGluR in functionally sufficient amounts.  
However, SH-SY5Y cells express metabotropic acetylcholine receptors (mAChR) 
(Ding et al., 1998; Leng et al., 2001), specifically the mAChR M3 (Edwardson and 
Szekeres, 1999), which as mGluR group I activates Gq, PLC and its downstream 
signalling cascade including the rise of cytoplasmatic Ca+2 concentration and 
activation of PKC.  The application of the mAChR agonist carbachol induced 
dopamine release from the SH-DAT cells in a dose-dependent manner (Figure 
11A). A summary of all agents tested for dopamine release can be found in Table 1.  
 
 
Figure 11 |  Dopamine release triggered by the mAChR agonist carbachol and its 
inhibition with chelerythrine in SH-DAT cells. A: dopamine release under a concentration series 
of carbachol. Although the EC50 was 30 µM, all the following experiments were done with 50 µM. 
B: The inhibitory response of chelerythrine when co-incubated at various concentrations with 50 
µM of carbachol. Half of the maximum possible inhibition (IC50) was achieved at 2.2 µM, 
however we used 4 µM for all the further experiments. The dash-line represents the 95% 
confidence interval of the curve. Error bars correspond to the standard deviation of a measurement 





The findings of this section substantiate our amperometric studies, and strengthen 
the evidences that a metabotropic neurotransmitter receptor is sufficient to induce 
the reversal of the DAT. 
Above we have shown that inhibition of PKC was sufficient to block the glutamate-
induced dopamine release in the SNr. In accordance with the amperometric 
recordings we were able to block carbachol-induced dopamine efflux in our SH-
DAT system using the non-selective protein kinase inhibitor staurosporine (n=4; 
p<0.01) or the selective PKC inhibitor chelerythrine (n=5; p<0.05) in a dose 
dependent fashion (Figure 11B).  
Even though we used chelerythrine concentrations that should make it selective to 
PKC, it could be argued that the effect we observed results from chelerythrine 
unspecific action. Thus we tested a different PKC inhibitor, bisindolylmaleimide I. 
And indeed, dopamine release induced by carbachol was also blocked by 
bisindolylmaleimide I (n=7; p<0.001). All three kinase inhibitors showed a 
significant block of the carbachol-induced dopamine efflux (Figure 12). Table 2 










Figure 12 | Dopamine release induced by carbachol is blocked by PKC inhibition in SH-
DAT cells. A: 1 µM of the non-selective kinase inhibitor staurosporine blocked dopamine release 
triggered by carbachol. B: Selective PKC inhibitor chelerythrine (4 µM) blocked carbachol-induced 
dopamine release. C: Bisindolylmaleimide I is a selective PKC inhibitor, which binds to the 
ATPase site, 1 µM of it blocks dopamine release induced by carbachol. All graphs are 
representative for the pharmacological agent assayed. The error bar represents the standard 
deviation of a triplicate wells measurement. One-way ANOVA with Tukey's Multiple Comparison 
Test was done. **p<0.01; ***p<0.001. Multiple experiments are summarized in table 1 and 2. 
 
To further investigate the role of PKC in the reversal of the DAT, we next tested 
alternative ways to activate PKC. We achieved to induce dopamine release from 
SH-DAT cells by the application of the diacylglicerol (DAG) analog OAG (n=3, 
p<0.05) and the PKC activator PMA (n=8, p<0.0001). In addition, 3M3FBS, a 
phospholipase C (PLC) activator, was also able to induce dopamine release (n=4, 
p<0.05) as depicted in Figure 13 and Table 1. 
In order to strengthen our previous results, dopamine released by any of these three 
agents was inhibited by 4 µM of the PKC inhibitor chelerythrine (Figure 13, Table 
2). The data presented up to here not only support that the reversal of the DAT can 
be induced by activation of a metabotropic receptor, but also that the manipulation 
of different elements of the signalling cascade indicates once more that PKC is an 






Figure 13 |  Chelerythrine inhibit all three activators of the Gq signalling cascade. A: 
Chelerythrine blocked the release of dopamine induced by 50 µM of the PLC activator 3M3FBS. 
B: Chelerythrine blocked dopamine release induced by 125 µM of the DAG analogue OAG. C: 
Chelerythrine blocked dopamine release induced by 8 µM of the PCK activator PMA. 
Chelerythrine was used at 4 µM. All graphs are representative for each pharmacological agent 
assayed. The error bar represents the standard deviation of a triplicate measurement. One-way 
ANOVA with Tukey's Multiple Comparison Test was done. *p<0.05; **p<0.01; ***p<0.001. 
Multiple experiments are summarized in Table 1 and 2. 
 
Since exocytosis can be PKC dependent in some cell types, we finally used reserpine 
to rule out a vesicular release mechanism. Reserpine inhibits the uptake of dopamine 
into vesicles through the vesicular monoamine transporter (VMAT). Reserpine was 
therefore added together with dopamine while loading the cells and during release. 
The presence of reserpine did not alter carbachol-induced dopamine release and did 






Figure 14 |  Reserpine does not affect carbachol-induced dopamine release or 
chelerythrine inhibition. Dopamine released by 50 µM carbachol compared to buffer application 
(Control) in presence or absence of reserpine. In order to exclude vesicular dopamine release after 
carbachol application, 10 µM of reserpine was used during the whole experiment, including 
dopamine uptake. One-way ANOVA was performed with Tukey´s all columns comparison test. 
ns= not significant differences. 
 
Recently published data from Gnegy et al. (2004) showed that cytosolic calcium is 
required for amphetamine-induced dopamine release. We have shown here that the 
activation of the Gq signalling cascade is sufficient to trigger dopamine efflux 
through the DAT, thus we explored the effect of dopamine release in our system 
under different calcium conditions. 
To test if an increase in cytosolic calcium would be sufficient to induce dopamine 
release, we tested the calcium ionophore ionomycin. Interestingly, dopamine release 
could also be induced by ionomycin (Figure 15, Table 1). Ionomycin-induced a 
robust dopamine release similar to carbachol. Inomycin-induced dopamine release 
was effectively inhibited by the PLC antagonist U73122 (n=4, p<0.01), by 
chelerythrine (n=8, p<0.05), but not by the calcium-calmodulin kinase II inhibitor 








Figure 15 |  Ca+2 ionophore ionomycin induced dopamine release in SH-DAT cells. A: 
Ionomycin dopamine release blocked by 10 µM of the PLC antagonist U73122. B: Ionomycin 
dopamine release blocked by 4 µM of the PKC inhibitor chelerythrine. C: The dopamine release 
induced by ionomycin was not blocked by 10 µM the CaMKII inhibitor KN-93. All graphs are 
representative for each pharmacological agent assayed. One-way ANOVA with Tukey's Multiple 
Comparison Test was done. *p<0.05; **p<0.01; ***p<0.001. 
 
This data indicates that the increase of intracellular calcium is sufficient to trigger 
dopamine release. However, the inhibition by U73122 and chelerythrine suggest 
that rise of intracellular calcium acts to some extent upstream of PKC. Overall, PKC 
appears to be the main candidate to help reversal of the DAT.  
The evidence that cytosolic calcium increase was able to trigger dopamine efflux 
leads to the question whether calcium influx is necessary for dopamine release. 
Carbachol-induced dopamine release was not affected when extracellular calcium 
was removed (Figure 16). This indicates that calcium influx is sufficient but not 






Figure 16 |  Dopamine release induced by carbachol is independent of extracellular 
calcium in SH-DAT cells. Carbachol induces dopamine to be released when compared to control 
condition in presence or absence of extracellular calcium. Carbachol-induced dopamine released is 
not different with or without extracellular calcium. Error bars represent the standard deviation of 
triplicate wells. One-way ANOVA with Tukey's Multiple Comparison Test was done.  
***p<0.001, ns = not significant. Carbachol was used at 50 µM and control is only the ringer 
buffer. 
 
Up to here we have demonstrated that PKC has a major role in the reversal of the 
DAT. However, how PKC induces dopamine release is still not answered. Several 
putative phosphorylation sites of the DAT (Granas et al., 2003) have been 
suggested. (Khoshbouei et al., 2004) showed that a deletion of the N-terminal first 
22 amino acids, harbouring 5 serine residues for potential phosphorylation, 
abolished the amphetamine-induced dopamine release. 
Accordingly, we generated a deletion of the first 19 residues of the DAT N-
terminus, which abolished the same putative phosphorylation sites.  We then 
created a SH-SY5Y stable transfected cell line with the new construct, which we 
called SH-D19.  
SH-D19 cells took up dopamine normally (Figure 17A). In addition, carbachol was 
able to induce a significant dopamine release comparable to SH-DAT (Figure 17B). 
This interesting finding differs completely from what has been shown for 
amphetamine (Khoshbouei et al., 2004; Cervinski et al., 2005) and suggests that N-
terminal phosphorylation of the DAT is not necessary for carbachol-induced 






Figure 17 | Dopamine uptake and carbachol-induced dopamine released in the DAT 
mutant SH-D19 cells. A: Dopamine uptake fits almost perfectly to an exponential decay curve. 
Gray dashed line indicates the 95% confidence intervals. Half-life of dopamine in the extracellular 
medium was 6.75minutes. B: Bars represent the standard deviation of triplicate wells 
measurements. Two-tailed unpaired Student t-test was performed. ***p<0.001.  
 
We then considered an alternative possible explanation, namely sodium influx 
through PKC activated ion channels. Since the DAT transports two sodium ions 
along with each dopamine molecule (Gu et al., 1994), rising intracellular sodium can 
be sufficient to reverse transport and induce release of dopamine (Elverfors et al., 
1997; Sonders et al., 1997; Khoshbouei et al., 2003). 
Transient receptor potential (TRP) channels are cation channels activated by PLC 
signalling. TRPC1, one of the classical subtypes, is phosphorylated by PKC 
(Ahmmed et al., 2004). Recently there has been evidence that TRPC1 is expressed 
on dopaminergic dendrites in the SN, colocalized with mGluR1 (Martorana et al., 
2006) and activated by mGluR1 in purkinje cells (Kim et al., 2003). Activation of 
mGluR1 in dopaminergic neurons led to a sodium-dependent EPSC that was 
blocked by nonselective TRP channel inhibitors, such as SKF98365 (Tozzi et al., 
2003). We therefore tested whether carbachol or PMA-induced release of 
dopamine from SH-DAT cells was sensitive to SKF98365. 20 µM of SKF98365 
did not block carbachol-induced or PMA-induced dopamine release (Figure 
18A&C). In contrast, 100 µM of the nonselective cation channel blocker lanthanum 






Figure 18 |  Effects on PMA and carbachol dopamine induced release by SKF98365 and 
lanthanum (La3+), non-selective TRP and cation channel blockers respectively. A: PMA 
induced significant dopamine release but is not inhibited by SKF98365. B: La3+ can block 
dopamine release induced by PMA. C: Carbachol-induced dopamine release is not inhibited by 20 
µM of the TRP channel inhibitor. D: Lanthanum block dopamine release induced by carbachol. 
Error bars represent the standard deviation of triplicate wells measurements. One-way ANOVA 
with Tukey's Multiple Comparison Test was done. *p<0.05. Concentrations: PMA 8 µM, carbachol 
50 µM, SKF98365 20 µM, La3+ 100 µM. 
 
This indicates that possibly a less SKF98365-sensitive TRP channel subtype may 
mediate PKC-induced sodium entry in DAT-SH cells or a totally different sodium 
channel is involved, which can also be opened after PKC phosphorylation. 
To further explore the role of sodium, we then removed extracellular sodium, after 
loading the cells with dopamine by replacing it with glucose (to achieve the same RB 




of extracellular sodium resulted in a greatly increased baseline dopamine efflux, even 
without addition of any drugs. In this condition, addition of PMA to the 0 mM Na+ 
medium did not significantly change the amount of dopamine released (Figure 19).  
 
Figure 19 | Effect of PMA in the 
absence of extracellular Na+. PMA has no 
effect in dopamine release when the sodium 
gradient is inversed (0 mM extracellular 
sodium). Error bars represent the standard 
deviation of triplicate wells. Unpaired 
Student t-test was performed. ns= no 




This can be interpreted in the sense that PMA and a change in sodium gradient are 
redundant because PMA acts through modifying the sodium gradient. However, it 
is also possible that the DAT capacity to release dopamine is completely utilized at 




Table 1 |  Dopamine release in SH-DAT 
Agent name Used concentration 
Dopamine release relative 
 to the control (%) 
n p value 
3M3FBS 50 µM 210.0  ± 38 n=4 <0.05  
OAG 125 µM 123.4  ± 16 n=3 <0.05 
PMA 8 µM 151.9  ± 16 n=8 <0.0001 
Ionomycin 5 µM 486 ± 106.5 n=16 <0.001 
Carbachol 50 µM 236.7  ± 46.9 n=7 <0.001 
Table 1 | Summary of different agents that triggered dopamine release in SH-DAT cells. 
3M3FBS is a PLC activator; OAG is a DAG analogue; PMA is a PKC activator; Ionomycin is a 
Ca+2 ionophore; Carbachol is a mAChR agonist. Cells were exposed to individual agents for 5 min 
in a humidified incubator at 37°C and 5% CO2. After this time extracellular dopamine was 
measured by HPLC with electrochemical detection. Statistic: n= independent experiment (each one 
with triplicate wells), p values were obtained using paired Student’s t-test between the agent and it 








Table 2 | Inhibition of induced dopamine release in SH-DAT cells. 
Inhibitors Agents that induce dopamine release in SH-DAT 
µM Names Carbachol Ionomycin 3M3FBS OAG PMA 
1 Staurosporine n=4; ** - - n=3, * n=4; ** 
4 Chelerythrine n=5; ** n=8, * n=7, * n=5, * n=4; ** 
1 Bisindolyl n=7; *** - - - - 
10 U73122 - n=4, ** - - - 
10 KN-93 - n=4, ns - - - 
Table 2 |  Summary of different blockers and agents that triggered dopamine release in SH-
DAT cells. Inhibitors: Staurosporine is a non-selective kinase inhibitor; Chelerythrine PKC  C2 
agonist; Bisindolyl= bisindolylmaleimide I, selective PKC inhibitor (ATPase domain); U73122 is a 
PLC inhibitor; KN93 is a CaMKII inhibitor.  Dopamine release inducers: 3M3FBS is a PLC 
activator; OAG is a DAG analogue; PMA is a PKC activator; Ionomycin is a Ca+2 ionophore; 
Carbachol is a mAChR agonist. Statistics: n= independent experiment (each one in triplicate), p 
values were obtained using paired Student’s t-test between the agent and its respective control 








Table 3 | Effect of reserpine, in induced dopamine release and blockade 
Parameter + reserpine - reserpine Comp. 
Release by carbachol 1.8 x ctrl (n=5) 
2.7 x ctrl 
(n=12) ns 
Release by ionomycin 5.1 x ctrl (n=4) 
5.7 x ctrl 
(n=11) ns 
Block of carbachol by chelerythrine 35% (n=2) 
39% 
(n=5) ns 
Block of ionomycin by chelerythrine 22% (n=2) 
34% 
(n=8) ns 
Table 3 |  Summary of the effect of reserpine in carbachol and ionomycin induced 
dopamine release and when they were blocked by chelerythrine. Carbachol is a mAChR 
agonist and was used at 50 µM; Ionomycin is a Ca+2 ionophore and was used at 5 µM; 
Chelerythrine is PKC antagonist and was used at 10 µM. Statistics: n= independent experiment 
(each one in triplicate). Comp. is the comparison obtained using two tailed and unpaired Student’s 
t-test; ns= no significant difference between the +reserpine and –reserpine. (buffer alone or with 





3.3. Studying dopamine transporter kinetics by fluorescence imaging 
As a new method to study dopamine transport, we used the fluorescent DAT 
substrate ASP+. This molecule is chemically similar to the toxic DAT substrate 
MPP+ and has been used to characterize binding and uptake by the transporters for 
dopamine and norepinephrine (Schwartz et al., 2003; Mason et al., 2005). ASP+ 
was applied to the extracellular buffer together with the cell-impermeable trypan 
blue, which quenched extracellular ASP+.  
In order to test the system, we had transiently transfected HEK293 cells with a 
plasmid that encodes the DAT and EGFP as separate proteins. This allowed us to 
have a mixed population of transfected and untransfected cells, where the EGFP 
positive cells expressed the DAT and the EGFP negative did not. The cells were 
exposed for several minutes to ASP+ in the presence of trypan blue. ASP+ was 
selectively taken up into DAT-expressing cells, reflected by an increase in 
intracellular ASP+ (figure 20).  
 
Figure 20 |  ASP+ is selective uptake by the DAT transfected HEK293 cells. Cells were 
transfected with a plasmid that encodes the DAT and EGFP as separate proteins. Images were 
acquired every 30 seconds. Cells were superfused with ringer buffer (RB) after 3 minutes 10 µM 
ASP and 30 µM trypan blue was superfused until the end of the experiment. The same 488-argon 
laser exited ASP+ and EGFP, but their emission maximums were well separated around 509 nm for 
EGFP and 580 nm for ASP+. Numbers in the figure represent minutes and the bar represents 20 





The characterization of Asp+ uptake by Schwartz and co-workers described first a 
very rapid increase in fluorescence that most likely represents the binding of ASP+ 
to the DAT. We observed the same conduct (Figure 21; box “a”). The second, a 
more gradual increase has been interpreted as the uptake of ASP+ into the cells 
(Figure 21; box “b”). Fluorescence increases because ASP+ is no longer quenched 
when it is bound to the DAT or taken up into the cells (Schwartz et al., 2003).  
ASP+ has so far not been considered as a tool to study release by transport, because 
once inside the cell, it rapidly binds to membranes and is taken up by mitochondria 
(Schwartz et al., 2003). 
However, when we applied amphetamine after only 1 minute of ASP+ uptake, this 
resulted in a strong (but not complete) release of the intracellular ASP+, reflected by 
the decrease of fluorescence intensity (Figure 21).  
 
 
Figure 21 |  Amphetamine-induced ASP+ release in SH-DAT cells. A representative trace 
shows the intensity of ASP+ of one single cell in arbitrary fluorescence units (AFU). Images were 
acquired at 0.3Hz. The arrows indicate the type and duration of the stimuli. Amphetamine was 
added together with ASP+ to rule out a diluting effect. The application of 50 µM of amphetamine 
for 1 minute was capable to generate a robust efflux of ASP+. Box “a” indicates the rise of 
fluorescence, in response to the binding of ASP+ to the DAT, and box “b” represents the actual 
DAT transport. 
 
The mechanism by which amphetamine reverses dopamine transport has been 
debated for a long time. Interestingly, the data obtained with this method give us 
some insights that were not intended originally. If the first fast rise of fluorescence is 
really due to the binding of ASP+ to the transporter, the remarkable drop in 




only induces dopamine (in this case ASP+) to move out of the cell, but also that 
amphetamine is a dopamine transporter substrate which displaces ASP+ from its 
binding site. This matter has not been fully resolved before (Sulzer et al., 2005).   
Interestingly, after the application of 50 µM carbachol we observed a similar, but 
less pronounced drop in fluorescence that the one obtained after the application of 
amphetamine (Figure 22) (n=3). 
 
 
Figure 22 |  Asp+ released after application of carbachol in SH-DAT cells. A: The trace 
shows the intensity of ASP+ of a single cell in arbitrary fluorescence units (AFU). Images 
acquisition frequency was 0.3Hz. The arrows indicate the type and duration of the stimulus. Box 
“a” indicates the rise of fluorescence, in response to the binding of ASP+ to the transporter, and 
box “b” represents the actual DAT transport. During the second ASP+ application, we also applied 
for 1 minute 50 µM carbachol diluted in the same ASP+ solution to avoid wash out of ASP+. A 
transient fall of fluorescence can be reproducibly observed after carbachol application (n=10 cells 
and n=4 independent experiments). A third ASP+ application was done to check the normal 
functioning of the system. B: Pictures representing the three different states of the fluorescence. 
The numbers 1, 2 and 3 indicated in A, represent: without ASP+, when ASP+ binds to the 
transporter and when ASP+ is inside the cells respectively. The bar represents approximately 20 
µM.    
 
We confirmed that ASP+ is a selective substrate of the DAT. We observed ASP+ 




DAT. Additionally, our evidence strongly suggests that carbachol is able to induce 
ASP+ release.  
To further characterize the carbachol effect, we also measured intracellular calcium 
changes using Fluo-4-AM in the SH-DAT. 
We applied glutamate to control for possible presence of mGluR or ionotropic 
glutamate receptor in SH-DAT cells, but there was no change in intracellular 
calcium during glutamate application. On the contrary, the application of carbachol 




Figure 23 | Intracellular calcium concentrations followed with AM-Fluo-4 calcium dye in 
SH-DAT cells. The trace shows the intensity of Fluo-4 of a single cell in arbitrary fluorescence 
units (AFU). Images acquisition frequency was 0.3Hz. The bars indicate the type and duration of 
the stimulus. 1 mM glutamate was applied during 1 minute and no changes in calcium can be 
observed. However 50uM carbachol was sufficient to trigger a strong calcium response. 
 
Even when carbachol was present during a minute, the cytosolic calcium seemed to 
be buffered after the first 15 seconds that carbachol was present. Interestingly we 
also observed in Figure 22 that during the application of carbachol the released 




new method permits to study the reversal of the DAT using imaging technique (in 
comparison with the traditional radioactive dopamine methods) and it might lead to 
a better understanding of the DAT kinetics. 
 
3.4. Physiological release of dopamine in the SN is mediated by the DAT  
The following data are not my original work, but the experiments were done in 
collaboration and as a result of my work. The purpose of this was to put the study in 
a physiological context.    
Whole cell patch clamp recordings were performed and analyzed by Lucian 
Medrihan (PhD student in Physiology Department, University of Göttingen). We 
used the modulation of spontaneous excitatory postsynaptic potentials (sEPSC) by 
dopamine D2 receptors as a sensitive way to measure the small amounts of 
dopamine released by spontaneous neuronal activity.  
Dopaminergic neurons receive glutamatergic afferents from the subthalamic nucleus 
(STN), which is spontaneously active (Falkenburger et al., 2001; Kass and Mintz, 
2006). This projection is modulated by presynaptic D2 receptors (Ibañez-Sandoval 
et al., 2006). Consequently, dopamine reduced the frequency of spontaneous 
EPSCs in dopaminergic neurons of the ventral tegmental area (VTA) (Koga and 
Momiyama, 2000). If in an undisturbed slice the DAT would be mainly taking up 
dopamine, blocking the DAT by GBR12935 would have a similar effect as 
exogenously applying dopamine and reduce the frequency of sEPSCs. Conversely, 
if the DAT would mainly release dopamine, GBR12935 would have the opposite 
effect and increase the frequency of sEPSCs. We observed the latter; GBR12935 
significantly increased the frequency of sEPSC (Figure 24A&B), suggesting that 
the DAT mediates mainly dopamine release in an unstimulated SNr slice 
preparation. Sulpiride had no further effect in the presence of GBR12935, 
indicating that with the DAT blocked extracellular dopamine concentration was too 




In summary, this experiment demonstrates that DAT-mediated dopamine release is 
induced by spontaneous neuronal activity in the slice and upholds a baseline 
concentration of extracellular dopamine. 
 
 
Figure 24 |  Spontaneous excitatory post-synaptic currents (sEPSC) of SNc dopaminergic 
neurons. A: Representative recordings of pharmacologically isolated spontaneous excitatory 
postsynaptic currents (sEPSCs) in pars compacta dopaminergic neurons from rat slices (in the 
presence of 1 µM bicuculine). 20 µM GBR12395 and 10 µM sulpiride were added in the bath after 
recording of stable controls. B,C: Relative frequency (B) and amplitude (C) of spontaneous EPSC 
in neurons treated consecutively with 20 µM GBR12909 and 10 µM sulpiride, A two-tailed paired 
t test was used for determining the statistical significance. (n/N = 6/3 for every column, where n is 




























In this study we have demonstrated that the activation of G-protein coupled 
receptors transiently changes the function of the DAT to a reverse mode. In contrast 
to amphetamine-induced dopamine release, N-terminal phosphorylation of the 
DAT by PKC was not necessary to induce DAT reversal. Instead, a PKC-
indueced influx of sodium appears to underlie dopamine efflux through the DAT. 
 
4.1.  The SNr’s DAT can function in reverse mode  
As an indirect way of measuring the small amounts of dopamine released in the SNr 
by STN spontaneous neuronal activity, we measured the modulation of excitatory 
postsynaptic potentials (sEPSC) by dopamine D2 receptors. In our experiments, the 
blockade of the DAT by GBR12935 was sufficient to increase the sEPSP 
frequency recorded in SNc neurons (Figure 24). Our interpretation of this result is 
that glutamatergic STN neurons induced physiologically the reversal of the DAT 
transport, since STN was shown to be spontaneously active (Falkenburger et al., 
2001) and its stimulation induced release of dopamine in the SNr (Mintz et al., 
1986).  
 
Figure 25 |  Cartoon representation of the D2 receptors des-inhibition after the application 
of GBR12935 and sulpiride. A: Spontaneous glutamate release from SNT afferents in the SNr 
leads to DAT-mediated dopamine release. Presynaptic and postsynaptic D2 receptors modulate the 
neuronal activity. B: GBR12935 blocks dopamine release. In consequence, the presynaptic and 
postsynaptic D2 receptors are no longer active, and they stop silencing the neurons. This leads to 
an increase in the spontaneous firing. C: The addition of the D2 antagonist sulpiride after 
GBR12935 did not change the effect induced by GBR12935 alone. This proposes that the 
extracellular concentration of dopamine after GBR12935 was too low to activate D2 receptors and 




The fact that GBR12935 decreased the dopamine levels in the SNr, suggest that 
dopamine is being released through the DAT. Moreover, we show that disturbances 
of the physiological DAT-mediated dopamine release are capable to modulate SNr 
activity. Our results are consistent with observations by Ibanez-Sandoval et al.. 
They showed that subthalamic-nigra projection is modulated by dopamine D2 
receptors (Ibañez-Sandoval et al., 2006).  
Using amperometric recordings in brain slices, we showed that the DAT could 
induce dopamine release after a local application of glutamate in the SNr (Figure 6). 
Dopamine release in the SN has been evidenced a long time ago (Geffen et al., 
1976; Cheramy et al., 1981), but the exact mechanism by which dopamine is 
released has been controversial. Our experiments show that the SNr dopamine 
release is present in the absence of calcium and is GBR12935 sensitive (Figure 6). 
Nevertheless, a calcium dependent dopamine release has been also shown in SNc 
neuronal soma (Jaffe et al., 1998) and also in the VTA (Rice et al., 1997).  
To further substantiate and investiagate DAT-mediated dopamine release we use 
our SH-DAT in vitro model. The neuroblastoma cell line expressing the dopamine 
transporter was capable to take up and release dopamine through the DAT (Figure 
9&10). Moreover, carbachol-induced dopamine release was insensitive to the 
VMAT inhibitor reserpine (Figure 14) and independent of extracellular calcium 
(Figure 16). These data suggest that vesicular release is not underlying carbachol-
induced dopamine release from SH-DAT cells. In coherence, independent 
evidences by Chen et al. (2001) and Falkenburger et al. (2001) showed dendritic 
dopamine release in the absence of extracellular calcium. Taking together, our 
physiological measurements with our in vitro characterization strongly suggest that 
dopamine can be released independent of vesicle fusion, mediated by the DAT and 






4.2. Second messenger cascade is involved in the reversal of the DAT 
4.2.1. metabotropic glutamate receptors  
Our observations of glutamate-induced dopamine release made us explore the 
possible implication of the mGluRs in the reversal of the DAT. Dopaminergic 
neurons primarily express mGluR class I, which consists of mGluR1 and mGluR5 
(Testa et al., 1994; Kosinski et al., 1998). We therefore used trans-ACPD as a 
group I selective agonist. Our observations demonstrate that an SNr local application 
of the mGluR group I agonist, was sufficient to induce DAT-mediated dopamine 
release in the brain slices (Figure 7). This is consistent with previous observations, 
where glutamate-induced dopamine release in the SNr was not altered by the 
inhibition of ionotropic glutamate receptors (AMPA and NMDA)(Falkenburger et 
al., 2001). 
The dopamine release signal we obtained by trans-ACPD application was relatively 
small when compared with the signal obtained after the application of glutamate or 
PMA. This can be explained by the lower potency of trans-ACPD to activate 
mGluRs. Pin et al. (1995) and Sayer et al. (1992), using patch-clamp recordings of 
mGluR-induced currents, have shown that trans-ACPD was 10 folds less potent 
than an equivalent concentration of glutamate in the activation of mGluRs (Sayer et 
al., 1992; Pin and Bockaert, 1995). For that reason, we also tried (S)-3,5-DHPG, 
which is another mGluR group I agonist, but unfortunately it produced an oxidative 
current signal by itself, disabling its use in the amperometric experiments. 
We decided to manipulate downstream elements of the mGluR group I signalling 
cascade. The local application of the PKC activator PMA resulted in a strong DAT-
mediated dopamine release (Figure 8). Accordingly, Cowell and co-workers (2000) 
also showed PMA-induced dopamine release in a striatal synaptosome preparation, 
suggesting that PKC activation can induce the DAT reversal (Cowell et al., 2000). 
We then showed that glutamate-induced dopamine release in the SNr could be 




glutamate-induced reversal of dopamine transport was mediated by PKC. 
Consistently, Kantor et al. (1998) showed in striatal synaptosomes preparation that 
amphetamine-mediated DAT reversal was dependent on PKC activity and 
extracellular calcium (Kantor and Gnegy, 1998). In contrast to Fog et al. (Fog et al., 
2006) we did not observe an inhibition of dopamine release with the CaMKII 
inhibitor KN-93. Differently than us, they drive the system by adding in the patch 
pipette additional activated or inactivated CaMKII and they also used a relatively 
high sodium concentration in the internal solution (30 mM), which would help in the 
DAT reversal. In addition, Fog and co-workers induced dopamine release with 
amphetamine. On our hand, DAT-mediated dopamine release in SNr seems to be 
linked with the PKC activation and not to CaMKII.  
 
4.2.2. Dissecting the signalling which induce the reversal of the DAT 
We used a neuronal cell line engineered with the human DAT to make a 
pharmacological study of the signalling involved in the reversal of the DAT. We 
obtained a DAT-mediated dopamine release in a dose-dependent manner by 
activating a muscarinic acetylcholine receptor (mAChR) (Figure 11A). We also 
observed a decrease in ASP+ cellular fluorescence intensity after carbachol 
application (Figure 22). The mAChR agonist carbachol activates M3 mAChR 
subtypes in SH-SY5Y cells. The M3 subtype has been shown to similarly as 
mGluR group I use the Gq-PLC signalling cascade (Edwardson and Szekeres, 
1999). This was evidenced when carbachol-induced dopamine release was dose-
dependently inhibited by chelerythrine (Figure 11B).  These results corroborate our 
amperometric findings, where PKC activation was necessary and sufficient for 
DAT-mediated dopamine release (Figure 12 & 13, Table 1). These independent 
additional findings support the general idea that PKC mediates the DAT reversal, 
and show that the upstream activators of PKC may differ. This last factor implies 




It is the advantage of the SH-DAT system that allowed the performance of a 
detailed pharmacological study (Table 1, 2 & 3). Overall, we observed dopamine 
release after the activation of each element of the Gq-PLC signalling cascade 
(Figure 13, Table 1). Additionally, induced dopamine release by the activation of 
PLC or PKC, was blocked by the PKC inhibitor chelerythrine (Figure 13, Table 2). 
An interesting finding was that the calcium ionophore ionomycin induced dopamine 
release and it was inhibited by the PLC antagonist U73122, which means that 
calcium operated upstream of PKC in the signalling cascade (Figure 15). These 
findings have unexpected implications for the understanding the mechanism of 
action for commonly used drugs. For instance, caffeine, a well-known “wakefulness” 
drug, releases calcium from intracellular stores and binds antagonicaly to adenosine 
receptors (A1 and A2) (Fisone et al., 2004). Furthermore, caffeine has been shown 
to be protective in MPTP animal models (Chen et al., 2001; Xu et al., 2002). Our 
result of the Gq-PLC-mediated transport reversal may be one explanation for this 
observation, since the rise of intracellular calcium induced DAT-mediated dopamine 
release (Figure 15). In addition to this, effects of caffeine alertness have not been 
studied in relation with an increase of extracellular neurotransmitters that are 
released by reversal transport.  
Our data demonstrates that activation of Gq-PLC signalling, either through 
muscarinic or metabotropic glutamate receptors, leads to DAT-mediated dopamine 
release. Furthermore, inhibition of PKC abolished the dopamine release induced by 
these G-protein coupled receptors (GPCR). PKC is ubiquitously expressed and its 
activation could in principle be triggered in several manners. This suggests that the 
transporter-mediated neurotransmitter release might be a general phenomenon in 





4.3. How does PKC activity induce DAT-mediated dopamine efflux? 
4.3.1. PKC direct DAT phosphorylation  
Our physiological and in vitro findings support PKC, but not CaMKII as an 
important element in the reversal of the DAT. It is important to note that the DAT 
has been shown to be phosphorylated by multiple kinases. However, this 
phosphorylation has been mainly implicated in the regulation of the DAT trafficking 
(Melikian and Buckley, 1999; Granas et al., 2003; Zahniser and Sorkin, 2004).  
We showed that direct phosphorylation after PKC activation, at least in the first five 
serine residues, was not necessary for Gq-PLC-induced dopamine release. The 
deletion of the first 19 amino acids of the DAT did not impair dopamine uptake and 
was not different in the carbachol-induced dopamine release paradigm (Figure 17). 
In contrary, a recent work of Khoshbouei et al. (2004) suggests that direct 
phosphorylation of N-terminal sites of the DAT sets the DAT into a “willing” state 
to induce amphetamine-mediated dopamine efflux. This outcome proposed, in 
contrary to our metabotropic-induced release, that N-terminal phosphorylation 
might induce sufficient conformational changes in the transporter to promote the 
“willing” state for amphetamine-induced dopamine release.  
Although the amphetamine and GPCR-induced dopamine release appears to 
diverge in their mechanism, certainly more experiments are needed to reach such 
conclusion. Especially because there are several additional phosphorylation 
candidates close to the transmembrane domain V (Figure 3 in the introduction), 
which we believe could trigger a conformation change that may be more relevant to 
dopamine transport than the one caused by phosphorylation of the flexible N-
terminus related to the amphetamine effect (Khoshbouei et al., 2004). Some of 
these conserved putative phosphorylation residues are part of the internal opening of 
the transition pore proposed (Jacobs et al., 2007). The latter suggests that the 
modification of this residue would be more likely to have an effect in the DAT 




4.3.2. Activation of PKC induced changes in sodium gradients 
As discussed in the previous section, PKC is a key element for the DAT reversal, 
but still not clear how it does it. While searching for a possible explanation of our 
DAT-phosphorylation-independent dopamine release mechanism, we thought that 
one possibility is that PKC activation lead to a change in the equilibrium of the 
DAT substrates. We know that increase in cytosolic dopamine from the vesicles 
(like the weak base hypothesis for amphetamine) was not the case since our 
experiment including reserpine did not altered the carbachol-induced dopamine 
release.  
However, we found that the non-selective cation channel blocker lanthanum 
inhibited GPCR-induced dopamine release (Figure 18). Influx of sodium could 
thus underlie the reversal of dopamine transport. This influx could be mediated by a 
PKC gated cation channel family, the TRP channels (Ahmmed et al., 2004). One 
member of the TRP family (TRPC1) is expressed in SNc neurons (Bengtson et al., 
2004) and activated by mGluR. Taking these together made the TRP channels 
good candidates to induce the reversal of the DAT.  
We could not inhibit the carbachol or PMA-induced dopamine release when the 
non-selective TRP channel blocker SKF98365, was used. This could be explained 
by the fact that the TRP channels expressed in SH-DAT cells are not blocked by 
our relatively low concentration of SKF98365.  
We also showed that carbachol was able to induce a similar DAT-mediated 
dopamine release in the presence or absence of extracellular calcium (Figure 16). 
This finding would discard calcium as one of the cations blocked by lanthanum, 
since TRP could let pass Ca+2 and Na+.  
Our experiments of lanthanum inhibition of PKC-induced dopamine release, 
together with the normal dopamine released observed in SH-D19 after carbachol 
stimulation, thus suggest that PKC might trigger a sodium influx rather than 




The DAT transport is in some extent also dependent on Cl-. Therefore, it is a 
possibility that the modification of chloride levels could lead to the DAT reversal. In 
addition, a neuron depolarization could also leads to a DAT-mediated dopamine 
release. These last two possibilities were not tested in this study, but they seem 
necessary to totally clarify the PKC-mediated reversal of the DAT. 
 
4.3.3. Parallels between DAT and GAT1 
Interestingly, Wu et al. (2006) recently showed in hippocampal neurons that the 
GABA transporter GAT1 keeps a tonic GABA release insensitive to vesicular 
fusion inhibition and sensitive to TTX. They conclude that GAT1 can drive GABA 
to the extracellular compartment, and this action entirely depends on the 
intracellular sodium concentration. Similar to the work of Wu and colleagues, we 
would need more experiments to identify the specific sodium channel that is 
involved in the process. Nevertheless, these findings are significant, since the 
mechanistic hypothesis of the PKC activation and the sodium increase for the 
reversal of the DAT can be conciliated.   
 
4.4. Physiological implications of the DAT reversal 
4.4.1. SNr physiology 
The subthalamic nucleus (STN) project glutamatergic efferents into the SNr, which 
are spontaneously active (Falkenburger et al., 2001; Kass and Mintz, 2006). We 
have shown that the blockade of the DAT in the SN brains slice leads to an increase 
of the sEPSP frequency (Figure 24 & 25). By doing this we were actually partially 
mimicking the case of PD and its loss of dopamineregic neurons. Less dopaminergic 





Importantly, the dopamine content in SNr has been shown to modulate whole 
animal behaviours For instance, Andersson and co-workers showed that dopamine 
depletion in the SNr reduced the rats’ motor performance in 58% when compared 
with control (Andersson et al., 2006). We propose with this study that the presence 
of dopamine in the SNr is mediated by the reversal of the dendritic DAT. Our 
amperometric data suggest that the local activation of an mGluR group I in the SNr 
induced a DAT-mediated dopamine release. Taking this into account, we can 
speculate than STN activity on the SNr could maintain a regular dopamine level in 
the SNr by reversing the DAT and that this dopamine could modulate different D1 
and/or D2 receptors present in the SNr. There are several evidences that show SNr 
dopamine capable to modulate neurons through D1 or D2 receptors on 
nigrothalamic (Ruffieux and Schultz, 1980), striatal (Martin and Waszczak, 1994), 
and subthalamic afferents (Ibañez-Sandoval et al., 2006).  
In Parkinson’s disease, the STN is hyperactive. This hyperactivity could partially 
compensate for the loss of dopaminergic neurons and uphold the dopamine 
concentration in the SNr. Consistently, nigral dopamine has been found less 
reduced following degeneration of dopaminergic neurons than striatal dopamine. 
 
4.4.2. Therapeutic treatments  
In our work we focus in a specific region of the brain, where the dendrites of the 
dopaminergic neurons are extended (SNr). Many widely used therapeutic drugs aim 
to block catecholamine transporters at the axonal terminals where catecholamine 
transporters are normally located and perform their uptake function.  
Our findings suggest that transporters located in dendrites or at the neuronal soma 
could have a physiological function by transiently reversing the direction of the 
monoamine translocation. If this is the case, the therapeutic effects observed with 




synaptic action, but also by blocking the release in non-classical neurotransmitter 
release as we have show in this study. 
Catecholamine inhibitors are extensively used, principally in the treatment of 
neuropsychiatric disorders including depressions, attention deficit hyperactive 
disorder (ADHD), addictions and eating disorders (Giros et al., 1992; Torres et al., 
2003). Many of them are synthetic compounds that where developed by mimicking 
the structures of natural substrates.  
Conversely, transporter blockers could have side effect resulting from the fact that 
they not only inhibit dopamine uptake but also dopamine release. For example, 
drugs that block the DAT could worsen symptoms of PD by reducing extracellular 






Dopaminergic neurons release their transmitter not only from axon terminals in the 
striatum but also from their long apical dendrites in the substantia nigra pars 
reticulata (SNr). Whether dendritic dopamine release is mediated by vesicle fusion 
or by the reversal of the dopamine transporter (DAT) remains controversial. 
Previous studies suggested that glutamate-induced dopamine release through the 
DAT was insensitive to ionotropic glutamate receptors inhibition. In this study we 
explored whether metabotropic glutamate receptors (mGluRs) are involved in 
DAT-mediated dendritic dopamine release. We used amperometric recordings to 
directly measure dopamine release in midbrain rat brain slices. Glutamate induced 
DAT-mediated dopamine release and was reversibly blocked by chelerythrine, a 
protein kinase C (PKC) inhibitor. A selective mGluR group I agonist induced 
dopamine release and was reversibly blocked by the DAT antagonist GBR12935. 
Additionally, the PKC activator PMA was also capable to elicit a DAT-mediated 
dopamine efflux. PKC-enhanced dopamine release has recently been associated 
with the effect of amphetamine on the DAT, but not with the activation of 
physiological mGluRs. To further decipher the responsible cell signalling elements of 
the reversal of the DAT, we generated stably transfected SH-SY5Y cells expressing 
a human wild-type DAT (SH-DAT). All metabotropic downstream signalling 
elements were able to induce dopamine release and were blocked by chelerythrine. 
To evaluate if PKC acts directly on the DAT, we generated a new stably 
transfected cell line only expressing a truncated dopamine transporter (SH-D19). 
Five serines, that were possible phosphorylation sites, were removed by deleting the 
first 19 N-terminal amino acids of the DAT. However, PKC-induced dopamine 
release was not affected in SH-D19, when compared with SH-DAT. Interestingly, 
PKC-induced dopamine efflux in SH-DAT cells was blocked when the non-
selective cation channel blocker, lanthanum (La+3) was present. Our findings suggest 
that PKC-induced dopamine release did not act by direct DAT phosphorylation. 




mediated by PKC gated cation channels like the transient receptor potential (TRP) 
channels. Throughout this work, we demonstrate that the activation of a second 
messenger signalling cascade leads to a reversal of the DAT. Since metabotropic 
receptors are widely expressed in the nervous system, the new concept on PKC-
mediated reversal transport, suggests that this phenomenon may also occur in other 
locations and with other neurotransmitters of the nervous system. Even more, this 
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